Cellceutix Corporation Welcomes Dr. Stephen T. Sonis to Its Scientific Advisory Board

BEVERLY, MA--(Marketwired - March 08, 2016) -  Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that Dr. Stephen T. Sonis, D.M.D., D.M.Sc., has joined the Cellceutix Scientific Advisory Board. Dr. Sonis is one of the world's foremost experts in the research and clinical treatment of cancer-related oral mucosal toxicities. He currently holds appointments at the Harvard School of Dental Medicine as Professor of Oral Medicine (part-time), and is a Senior Surgeon at the Dana-Farber Cancer Institute and Brigham and Women's Hospital .

Dr. Sonis also is a Founder and Chief Scientific Officer of Biomodels, LLC, a preclinical contract research organization that evaluates novel drugs for pharmaceutical and biotechnology companies. Widely respected by his professional peers, he is the author of over 250 original publications, reviews and chapters, 11 books, and 5 patents, serves on a number of editorial boards, and is a founding member of the International Society of Oral Oncology and the International Academy of Oral Oncology.

Dr. Sonis is a graduate of Tufts University and Harvard University and completed his post-doctoral education at Oxford University.

"Cellceutix is pleased to welcome Dr. Sonis to our team," said Leo Ehrlich, Cellceutix Chief Executive Officer. "Dr. Sonis is arguably the world's foremost expert on cancer-related oral mucositis. Of equal importance, he is no stranger to Brilacidin, having helped research its oral rinse formulation and application prior to Cellceutix's acquisition of the compound in 2013. His expertise in clinical study design and execution will be invaluable as Brilacidin-Oral Mucositis (OM) continues to be evaluated in an ongoing Phase 2 FDA trial."

Brilacidin-OM, which has been granted Fast Track status by the FDA, is an oral rinse formulation of the Company's lead defensin-mimetic, Brilacidin, for the prevention of oral mucositis in patients with head and neck cancer. Oral mucositis is a common and often debilitating inflammation and ulceration that occurs in the mouth as a side-effect of certain cancer treatments, afflicting approximately 450,000 patients each year in the United States. Its occurrence can severely affect the course and outcome of cancer therapy, not to mention has painful and debilitating effects on patients. There are no FDA-approved drugs for the prevention of oral mucositis in patients being treated for head and neck cancer.

"I'm very pleased to be able to continue my involvement in the development of Brilacidin as a member of Cellceutix's Scientific Advisory Board" remarked Dr. Sonis. "The need for an effective intervention for mucositis is pressing and, based on our pre-clinical testing of the drug, we're hopeful that Brilacidin will be successful in dealing with this significant unmet need."

More information about the Phase 2 Trial of Brilacidin for Oral Mucositis

https://clinicaltrials.gov/ct2/show/NCT02324335?term=cellceutix&rank=2

Alerts:

Sign-up for Cellceutix email alerts is available at http://cellceutix.com/email-alerts/#sthash.CRfqSmmY.dpbs

About Cellceutix:
Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol "CTIX". Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix's anti-cancer drug Kevetrin concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Cellceutix is now preparing its FDA application for a Phase 2 ovarian cancer study. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Cellceutix is in a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of Oral Mucositis in patients with head and neck cancer. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix's anti-psoriasis drug Prurisol is in a Phase 2 trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix's lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at www.cellceutix.com.

Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause Cellceutix's actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. Cellceutix has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are Cellceutix's need for, and the availability of, substantial capital in the future to fund its operations and research and development; including the amount and timing of the sale of shares of common stock to Aspire Capital; the fact that Cellceutix's compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in Cellceutix's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Cellceutix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.